JP2009518025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518025A5 JP2009518025A5 JP2008543894A JP2008543894A JP2009518025A5 JP 2009518025 A5 JP2009518025 A5 JP 2009518025A5 JP 2008543894 A JP2008543894 A JP 2008543894A JP 2008543894 A JP2008543894 A JP 2008543894A JP 2009518025 A5 JP2009518025 A5 JP 2009518025A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- dom7r
- ligand
- dom7h
- single variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003446 ligand Substances 0.000 claims description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims 36
- 108060003951 Immunoglobulin Proteins 0.000 claims 22
- 102000018358 immunoglobulin Human genes 0.000 claims 22
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 8
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 239000003053 toxin Substances 0.000 claims 8
- 231100000765 toxin Toxicity 0.000 claims 8
- 108700012359 toxins Proteins 0.000 claims 8
- 102000001301 EGF receptor Human genes 0.000 claims 7
- 108060006698 EGF receptor Proteins 0.000 claims 7
- 230000001717 pathogenic effect Effects 0.000 claims 7
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102100035721 Syndecan-1 Human genes 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 5
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 5
- 238000012377 drug delivery Methods 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 102000004225 Cathepsin B Human genes 0.000 claims 2
- 108090000712 Cathepsin B Proteins 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000007913 intrathecal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000037317 transdermal delivery Effects 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 239000000906 photoactive agent Substances 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74299205P | 2005-12-06 | 2005-12-06 | |
| PCT/GB2006/004565 WO2007066109A1 (en) | 2005-12-06 | 2006-12-05 | Bispecific ligands with binding specificity to cell surface targets and methods of use therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518025A JP2009518025A (ja) | 2009-05-07 |
| JP2009518025A5 true JP2009518025A5 (https=) | 2010-01-07 |
Family
ID=37820651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008543894A Pending JP2009518025A (ja) | 2005-12-06 | 2006-12-05 | 細胞表面標的に対して結合特異性を有する二重特異性リガンドおよびその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100021473A1 (https=) |
| EP (1) | EP1963370A1 (https=) |
| JP (1) | JP2009518025A (https=) |
| KR (1) | KR20080090414A (https=) |
| CN (2) | CN101426815A (https=) |
| AU (1) | AU2006323415A1 (https=) |
| BR (1) | BRPI0619460A2 (https=) |
| CA (1) | CA2632424A1 (https=) |
| CR (1) | CR10100A (https=) |
| EA (1) | EA200801171A1 (https=) |
| MA (1) | MA30020B1 (https=) |
| NO (1) | NO20082381L (https=) |
| TW (1) | TW200738750A (https=) |
| WO (1) | WO2007066109A1 (https=) |
| ZA (1) | ZA200804307B (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| CA2505316C (en) | 2002-11-08 | 2014-08-05 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| EP2240516B1 (en) | 2007-12-26 | 2015-07-08 | Biotest AG | Methods and agents for improving targeting of cd138 expressing tumor cells |
| ES2526433T3 (es) * | 2007-12-26 | 2015-01-12 | Biotest Ag | Inmunoconjugados dirigidos a CD138 y usos de los mismos |
| CA2710453C (en) * | 2007-12-26 | 2019-07-02 | Biotest Ag | Agents targeting cd138 and uses thereof |
| JP2011507933A (ja) * | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| CA2711256C (en) | 2008-01-03 | 2019-01-15 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| EP2346526A2 (en) | 2008-09-22 | 2011-07-27 | Massachusetts Institute of Technology | Compositions of and methods of using ligand dimers |
| BRPI0919714A2 (pt) * | 2008-10-21 | 2015-12-08 | Domantis Ltd | domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, ácido nucleico, vetor, célula hospedeira, e, método para produzir um polipeptídeo |
| CA2767752C (en) * | 2009-02-19 | 2020-07-07 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| NZ613647A (en) * | 2009-05-06 | 2015-02-27 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| AU2013201618B2 (en) * | 2009-05-06 | 2016-06-02 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| US9029328B2 (en) | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| MX358680B (es) | 2011-12-08 | 2018-08-31 | Biotest Ag | Usos de inmunoconjugados dirigidos a cd138. |
| AU2013271428B2 (en) * | 2012-06-07 | 2016-08-04 | Duke University | Human bispecific EGFRvIII antibody engaging molecules |
| TWI660972B (zh) * | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| ITFI20120257A1 (it) * | 2012-11-26 | 2014-05-27 | Maria Barbara Carnemolla | Anticorpo ricombinante umano e suo uso per l¿identificazione di syndecano-1 (cd-138) per scopi diagnostici e terapeutici. |
| BR112015023752B1 (pt) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
| CN105814082A (zh) * | 2013-09-26 | 2016-07-27 | 埃博灵克斯股份有限公司 | 双特异性纳米抗体 |
| CN105175546A (zh) * | 2015-05-27 | 2015-12-23 | 连祺周 | 人血管内皮生长因子与表皮生长因子样结构域7的融合蛋白 |
| MA43219A (fr) * | 2015-11-10 | 2018-09-19 | Univ Medical Center Hamburg Eppendorf | Polypeptides de liaison d'antigène dirigés contre cd38 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| US20190225701A1 (en) | 2016-09-26 | 2019-07-25 | The Brigham And Women's Hospital, Inc. | Regulators of b cell-mediated immunosuppression |
| CN109789183A (zh) | 2016-09-29 | 2019-05-21 | Aebi有限公司 | 治疗性多靶向构建体及其用途 |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| WO2019035938A1 (en) * | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| KR20200044094A (ko) * | 2017-09-13 | 2020-04-28 | 테네오바이오, 인코포레이티드 | 엑토효소에 결합하는 중쇄 항체 |
| MX2020013248A (es) * | 2018-06-05 | 2021-04-13 | Novobind Livestock Therapeutics Inc | Anticuerpos contra agentes patogenos en acuacultura y sus aplicaciones. |
| CN109134611B (zh) * | 2018-08-14 | 2021-08-03 | 江苏大学 | 特异性结合egfr抑制egf促肿瘤细胞增殖的多肽 |
| BR112021000173A2 (pt) * | 2018-10-26 | 2021-05-04 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd38 |
| MX2021005242A (es) | 2018-11-05 | 2021-06-08 | Xyphos Biosciences Inc | Receptores nkg2d no naturales que no señalizan directamente las células a las que se unen. |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| CN111732662B (zh) * | 2020-06-11 | 2023-09-15 | 军事科学院军事医学研究院军事兽医研究所 | 抗H5N1病毒入胞抗体PTD-7B-mFc及其应用 |
| FR3120866B1 (fr) * | 2021-03-19 | 2025-02-28 | Univ Toulouse 3 Paul Sabatier | Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2263984T3 (es) * | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| ES2533963T3 (es) * | 2002-10-10 | 2015-04-16 | Merck Patent Gmbh | Composiciones farmacéuticas dirigidas a receptores Erb-B1 |
| WO2005044858A1 (en) * | 2003-11-07 | 2005-05-19 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
-
2006
- 2006-12-05 US US12/086,115 patent/US20100021473A1/en not_active Abandoned
- 2006-12-05 EA EA200801171A patent/EA200801171A1/ru unknown
- 2006-12-05 TW TW095145117A patent/TW200738750A/zh unknown
- 2006-12-05 BR BRPI0619460-5A patent/BRPI0619460A2/pt not_active IP Right Cessation
- 2006-12-05 CN CNA200680052392XA patent/CN101426815A/zh active Pending
- 2006-12-05 JP JP2008543894A patent/JP2009518025A/ja active Pending
- 2006-12-05 AU AU2006323415A patent/AU2006323415A1/en not_active Abandoned
- 2006-12-05 WO PCT/GB2006/004565 patent/WO2007066109A1/en not_active Ceased
- 2006-12-05 CA CA002632424A patent/CA2632424A1/en not_active Abandoned
- 2006-12-05 EP EP06808727A patent/EP1963370A1/en not_active Withdrawn
- 2006-12-05 KR KR1020087016535A patent/KR20080090414A/ko not_active Withdrawn
- 2006-12-05 CN CNA2006800523775A patent/CN101379088A/zh active Pending
-
2008
- 2008-05-19 ZA ZA200804307A patent/ZA200804307B/xx unknown
- 2008-05-26 NO NO20082381A patent/NO20082381L/no not_active Application Discontinuation
- 2008-06-02 MA MA30989A patent/MA30020B1/fr unknown
- 2008-06-20 CR CR10100A patent/CR10100A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518025A5 (https=) | ||
| Li et al. | Transferrin receptor 1 targeted nanomedicine for brain tumor therapy | |
| Wadajkar et al. | Tumor‐targeted nanotherapeutics: overcoming treatment barriers for glioblastoma | |
| JP2009518024A5 (https=) | ||
| JP2009519011A5 (https=) | ||
| JP2009517069A5 (https=) | ||
| US20120171201A1 (en) | Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin | |
| CN107073132A (zh) | 载体‑抗体组合物及其制备和使用方法 | |
| US20220143197A1 (en) | siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer | |
| WO2015070210A1 (en) | Epha3 and multi-valent targeting of tumors | |
| US11472862B2 (en) | IL13Rα2 peptide and its uses | |
| McGonigle et al. | Neuropilin-1 drives tumor-specific uptake of chlorotoxin | |
| Frank et al. | Strategies for enhancing antibody delivery to the brain | |
| CN103372199A (zh) | 一种预防和治疗神经退行性疾病的新型脑部靶向制剂 | |
| JP2022545055A (ja) | ＰＲＤＭ１４タンパク質の発現をダウンレギュレートする標的化ｓｉＲＮＡ製剤を使用する癌処置 | |
| AU2020315947A1 (en) | Methods and compositions for treating cancer using peptide nucleic acid-based agents | |
| EP3473274B1 (en) | Antibody-drug composite platform using bispecific antibody | |
| AU2021276573A1 (en) | Tnfalpha immunoconjugate therapy for the treatment of brain tumors | |
| JP7239987B2 (ja) | 薬物送達のための抗体融合タンパク質 | |
| CN116832177A (zh) | 干扰趋化素样因子超家族成员6(cmtm6)表达的基因治疗载体的制备和抗肿瘤应用 | |
| US12448425B2 (en) | Therapeutic peptides | |
| CN109982720A (zh) | 抗体药物缀合物 | |
| EA026453B1 (ru) | Применение окисленного авидина для ингаляции | |
| Latulippe et al. | Kinin agonists as a means to increase blood–brain barrier permeability of drugs | |
| JPWO2021222295A5 (https=) |